Antonio Postigo
ICREA-IDIBAPSPublicaciones destacadas
-
ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells
Autores: de Barrios O, Sanchez-Moral L, Cortés M, Ninfali C, Profitós-Pelejà N, Martínez-Campanario MC, Siles L, Del Campo R, Fernández-Aceñero MJ, Darling DS, Castells A, Maurel J, Salas A, Dean DC, Postigo A .Referencia: Gut 2019. -
ZEB1 protects skeletal muscle from damage and is required for its regeneration
Autores: Siles, L; Ninfali, C; Cortes, M; Darling, DS; Postigo, A.Referencia: Nature Communications 2019. -
Regulation of muscle atrophy-related genes by the opposing transcriptional activities of ZEB1/CtBP and FOXO3
Autores: Ninfali C; Siles L; Darling D; Postigo A.Referencia: Nucleic Acids Research 2018. -
Mitotic polarization of transcription factors during asymmetric division establishes fate of forming cancer cells
Autores: Liu Y; Siles L; Lu X; Dean K; Cuatrecasas M; Postigo A; Dean D.Referencia: Nature Communications 2018. -
Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles
Autores: Cortes, Marlies; Sanchez-Moral, Lidia; de Barrios, Oriol; Fernandez-Acenero, Maria J.; Martinez-Campanario, M. C.; Esteve-Codina, Anna; Darling, Douglas S.; Gyorffy, Balazs; Lawrence, Toby; Dean, Douglas C.; Postigo, Antonio;.Referencia: Embo Journal 2017. -
ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1
Autores: De Barrios O., Gyorffy B., Fernández-Aceñero M.J., Sánchez-Tilló E., Sánchez-Moral L., Siles L., Esteve-Arenys A., Roué G., Casal J.I., Darling D.S., Castells A., Postigo A..Referencia: Gut 2017. -
Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis
Autores: Liu Y., Lu X., Huang L., Wang W., Jiang G., Dean K.C., Clem B., Telang S., Jenson A.B., Cuatrecasas M., Chesney J., Darling D.S., Postigo A., Dean D.C..Referencia: Nature Communications 2014. -
The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma
Autores: Sanchez-Tillo, E; Fanlo, L; Siles, L; Montes-Moreno, S; Moros, A; Chiva-Blanch, G; Estruch, R; Martinez, A; Colomer, D; Gyorffy, B; Roue, G; Postigo, A.Referencia: Cell Death And Differentiation 2014. -
ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1
Autores: Sanchez-Tillo, Ester; de Barrios, Oriol; Siles, Laura; Amendola, Pier G; Darling, Douglas S; Cuatrecasas, Miriam; Castells, Antoni; Postigo, Antonio.Referencia: Clinical Cancer Research 2013. -
β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.
Autores: Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A .Referencia: Proceedings Of The National Academy Of Sciences Of The United States Of America 2011.
Proyectos destacados
-
EMT factors beyond the tumor cell: Do (and how) ZEB factors regulate the plasticity and reprogramming of tumor-associated factors (TAMs) from tumor-suppressor TAMs to immuno-suppressor TAMs
Investigador/a principal: Antonio PostigoFinanciador: Ministerio de Ciencia e Innovación (Ministry of Science)Código: PID2020-116338RB-I00Duración: 01/09/2021 - 31/08/2024 -
Cooperation and competition between colorectal carcinomas (CRC) and their tumor microenvironment: Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC.
Investigador/a principal: Antonio PostigoFinanciador: Fundació Olga TorresCódigo: Beca Bianual 2019-Modalitat ADuración: 01/01/2020 - 31/12/2021 -
Validation of ZEB factors as prognostic and predictive biomarkers and therapeutic targets in CRC
Investigador/a principal: Antonio PostigoFinanciador: Asociación Española Contra el Cáncer (AECC).Código: Proyectos AECC 2019Duración: 01/11/2019 - 31/10/2022 -
Validation of ZEB2 as a predictive predictive biomarker and potential therapeutic target in Duchenne muscular dystrophy
Investigador/a principal: Antonio PostigoFinanciador: Duchenne Parent ProjectCódigo: DPP-E-2018Duración: 16/12/2018 - 15/12/2020